Glenmark Pharma Q1 FY27 Revenue Jumps 23.1% to ₹4018.5 Crore
Glenmark Pharmaceuticals reported Q1 FY27 consolidated revenue of ₹4018.5 crore, up 23.1% YoY. EBITDA grew 38.6% to ₹804.8 crore, with PAT at ₹482.8 crore. India formulations revenue rose 15.5%, North America 41.1%, Europe 11.9%, and Emerging Markets 27.7%. Management cited broad-based growth and strategic focus on core businesses and innovation.
The announcement details significant financial performance improvements with double-digit growth across multiple regions and key financial metrics, which is likely to have a substantial impact on investor sentiment and the company's stock.
The company reported strong year-on-year growth in revenue, EBITDA, and PAT, driven by robust performance across its key markets. Positive commentary from the Chairman & Managing Director further reinforces the optimistic outlook.
Glenmark Pharmaceuticals Limited announced its financial results for the first quarter ended June 30, 2026. The company reported a consolidated revenue of ₹40,185 million (₹4018.5 crore), a 23.1% year-on-year growth from ₹32,644 million in the corresponding quarter last year. EBITDA for the quarter was ₹8,048 million, marking a 38.6% YoY increase, with an EBITDA margin of 20.03%. Profit After Tax (PAT) stood at ₹4,828 million, resulting in a PAT margin of 11.8%.
Key growth drivers included a 15.5% YoY increase in India Formulations revenue to ₹14,321 million, and robust growth in North America, which grew by 41.1% YoY to ₹10,974 million. Europe revenue increased by 11.9% YoY to ₹7,472 million, while Emerging Markets saw a significant rise of 27.7% YoY to ₹7,304 million.
Commenting on the results, Glenn Saldanha, Chairman & Managing Director, highlighted broad-based growth across key markets, strong execution, and business resilience. He noted India's outperformance, North America's robust underlying growth driven by respiratory launches, and sustained momentum in Emerging Markets. Saldanha emphasized the company's focus on strengthening core businesses while expanding differentiated specialty and innovation-led platforms, citing the growth of RYALTRIS®, WINLEVI®, and progress in the oncology portfolio.
What to do with a filing like this
Glenmark Pharmaceuticals Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Glenmark Pharmaceuticals Limited. Read the original for the full detail.